Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsNew findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.
A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.
FDA Approves First Dual-Agent Eye Drop for Near Vision Loss
1.
Except for Black Patients, the Rates of Gallbladder Cancer Are Stable or Declining.
2.
The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.
3.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
4.
Rising rates of head and neck cancers in England
5.
Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.
1.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
2.
Tertiary Lymphoid Structures: Pivotal Players in Cancer Prognosis and Therapeutic Response
3.
The Science Behind Imatinib: How It Targets Cancer Cells
4.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
5.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
Understanding the causes of anemia in adults beyond nutritional deficiencies
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge